Showing 1971-1980 of 5771 results for "".
- GenSight Biologics Announces Publication of Results from Lumevoq RESCUE Phase 3 Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-rescue-phase-3-trial/2478755/GenSight Biologics announced that Ophthalmology has published results from the RESCUE pivotal phase 3 clinical trial of Lumevoq gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper, published in the January issue under the title, “Efficacy and safety
- Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-first-patients-enrolled-in-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478744/Clearside Biomedical announced that the first patients have been enrolled in its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). Clinical sites, all based in the United States, are activated and curr
- Aviceda Therapeutics Announces Formation of Executive Teamhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-executive-team/2478745/Aviceda Therapeutics has announced the composition of the Executive Team that will guide the company through ongoing development of first-in-class therapeutics and continued growth opportunities as a business entity. Aviceda’s lead ophthalmic optimized nanoparticle, as an intravitreal form
- Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for Investigational Dry AMD Treatmenthttps://modernod.com/news/gemini-therapeutics-announces-fda-fast-track-designation-granted-for-gem103-for-investigational-dry-amd-treatment/2478737/Gemini Therapeutics announced that GEM103, the company’s investigational treatment for dry AMD, has been granted Fast Track designation by the FDA. Gemini is evaluating GEM103, a recombinant, human complement factor H (CFH), for its ability to address the multiple AMD pathobiologies in gene
- Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facilityhttps://modernod.com/news/adverum-biotechnologies-announces-new-gmp-gene-therapy-manufacturing-facility/2478734/Adverum Biotechnologies announced plans for a new Good Manufacturing Practices facility in Durham, North Carolina. Adverum will invest over $80 million in the 174,000-square-foot facility, located in Research Triangle Park (RTP). The site will include four 1,000-liter bioreactors, with space for
- Kala Pharmaceuticals Announces Commercial Availability of Eysuvis for the Treatment of Dry Eye Diseasehttps://modernod.com/news/kala-pharmaceuticals-announces-commercial-availability-of-eysuvis-for-the-treatment-of-dry-eye-disease/2478729/Kala Pharmaceuticals announced the launch of Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease. Eysuvis is now available in national and
- EyeCare Associates of East Texas Announces Partnership With Private Equity Firm EyeCare Partnershttps://modernod.com/news/eyecare-associates-of-east-texas-announces-partnership-with-private-equity-firm-eyecare-partners/2478721/Brown Gibbons Lang & Company (BGL) has announced a new partnership between EyeCare Associates of East Texas (ECA) and EyeCare Partners (ECP) resulting in the addition of ECA’s four Texas clinics to ECP’s national ne
- Midwest Vision Partners Announces Partnership With Parschauer Eye Centerhttps://modernod.com/news/midwest-vision-partners-announces-partnership-with-parschauer-eye-center/2478711/Midwest Vision Partners (MVP) has announced its partnership with Parschauer Eye Center—MVP’s eighth partnership to date. MVP is an eye care management services organization that partners with ophthalmologists and optometrists in the Midwest. MVP’s partnership with Parschauer Eye Center expands it
- Haag-Streit UK Announces the Launch of the iVue80 in the UKhttps://modernod.com/news/haag-streit-uk-announce-the-launch-of-the-ivue80-in-the-uk/2478697/Haag-Streit UK has announced the launch of the new iVue80 OCT in the UK. The iVue80 SD-OCT system offers 80,000 A-scans per second—three times faster than the original iVue model—and offers improved efficiency and enhanced image quality. The system also features new scan options and functions, a
- Innovent Announces NMPA Granted New Indication Approvals for Sulinno for the Treatment of Pediatric Plaque Psoriasis and Noninfectious Uveitishttps://modernod.com/news/innovent-announces-nmpa-granted-new-indication-approvals-for-sulinno-for-the-treatment-of-pediatric-plaque-psoriasis-and-noninfectious-uveitis/2478695/Innovent Biologics announced that Sulinno (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for two new indications, including the treatment